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OBJECTIVE — We report the independent risk association of type 2 diabetic nephropathy
with the z2 allele of the 5-(CA)n microsatellite and C-106T promoter polymorphisms of the
aldosereductasegene(ALR2)usingacase-controldesign.Inthisexpandedcohort,weexamined
their predictive roles on new onset of cardiorenal complications using a prospective design.
RESEARCH DESIGN AND METHODS — In this 8-year prospective cohort of 1,074
type 2 diabetic patients (59% male, median age 61 years; disease duration 7 years) with an
observation period of 8,592 person-years, none had clinical evidence of coronary heart disease
(CHD) or chronic kidney disease at recruitment. The renal end point was deﬁned as new onset
of estimated glomerular ﬁltration rate 60 ml/min per 1.72 m
2 or hospitalizations with dialysis
or death due to renal disease, and CHD was deﬁned as hospitalizations with myocardial infarc-
tion, ischemic heart disease, or related deaths.
RESULTS — After controlling for baseline risk factors and use of medications, we found that
theALR2z2alleleof(CA)nmicrosatellitecarriershadincreasedriskofrenal(hazardratio1.53
[95% CI 1.14–2.05], P  0.005) or combined cardiorenal (1.31 [1.01–1.72], P  0.047) end
points. Carriers of the ALR2 C-106T polymorphism also had increased risk of renal (1.54
[1.15–2.07], P  0.004) and cardiorenal (1.49 [1.14–1.95], P  0.004) end points. Compared
with noncarriers, patients with two risk-conferring genotypes had a twofold increased risk of
renal (2.41 [1.57–3.70], P  0.001) and cardiorenal (1.94 [1.29–2.91], P  0.002) end points.
CONCLUSIONS — In Chinese type 2 diabetic patients, genetic polymorphisms of ALR2
independently predicted new onset of renal and cardiorenal end points, with the latter being
largely mediated through renal disease.
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C
ardiovascular diseases and end-
stage renal disease (ESRD) are the
main causes of mortality and mor-
bidity in diabetic patients. The onset of
chronic kidney disease (CKD) markedly
increases the risk of cardiovascular dis-
ease as a result of further perturbation in
the metabolic milieu and vascular ho-
meostasis (1). In type 2 diabetes, control
ofhyperglycemiareducesproteinuriaand
therateofdeclineinrenalfunction(2).In
type 1 diabetes, established renal lesions
were reversed with restoration of normo-
glycemia after pancreatic transplantation
(3). Aldose reductase (ALR2) converts
glucose to sorbitol, especially under hy-
perglycemic condition. Accumulation of
sorbitol can lead to increased oxidative
and osmotic stresses, causing cataract,
microvascular complications, and myo-
cardial ischemic injury (4).
In a case-control cohort consisting of
92 Chinese type 2 diabetic patients with-
out nephropathy despite long disease du-
ration and 121 patients with both
retinopathy and nephropathy, the z2
allele of 5-(CA)n microsatellite and pro-
moter C-106T polymorphisms of the
ALR2geneindependentlyconferredarisk
of diabetic nephropathy (5). In this ex-
panded consecutive cohort of 1,074 type
2diabeticpatientswithdocumentationof
risk factors, complications, and clinical
outcomes, we examined the independent
andadditiveeffectsofthesetwopolymor-
phisms of the ALR2 gene on cardiorenal
end points after an 8-year observational
period.
RESEARCH DESIGN AND
METHODS
Hong Kong Diabetes Registry
This registry was established in 1995 as
part of a quality improvement program
basedontheEuropeanDIABCAREproto-
col and accompanied by a DNA bank do-
nated by patients with written informed
consent. Using this registry, we have re-
ported the use of clinical and biochemical
markers to predict cardiorenal complica-
tions (6–8). The study was approved by
the Chinese University of Hong Kong
Clinical Research Ethics Committee. The
recruitment methods, deﬁnitions, and
biochemical and genetic assays have been
described previously (5,7).
Clinical and biochemical
assessments and genotyping
After an 8-h overnight fast, patients were
seen in the unit for measurement of BMI,
waist circumference, and blood pressure
after at least 5 min of rest. Hypertension
was deﬁned as blood pressure 140/90
mmHg and/or treatment with antihyper-
tensive drugs. A family history of coro-
nary heart disease (CHD) was deﬁned as
premature heart disease in ﬁrst-degree
relatives aged 60 years. Peripheral arte-
rial disease was deﬁned by a history of
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pulses conﬁrmed by an ankle-to-brachial
ratio0.90usingDopplerultrasound,or
revascularization. Sensory neuropathy
was deﬁned by two of three features: ab-
normal sensation in the extremities, re-
duced vibration sense 6/8 (or 4/8 for
those aged 65 years) using a graduated
tuning fork, or abnormal sensation to
monoﬁlamentonanypartofthesolewith
a normal skin surface. An eye examina-
tion was performed by use of either fun-
dus photography or direct viewing using
an ophthalmoscope by ophthalmologists
or trained medical personnel. Retinopa-
thy was deﬁned by typical retinal
changes, including laser scars or a history
of vitrectomy.
The albumin-to-creatinine ratio
(ACR) was measured in a sterile, random,
spot urine sample conﬁrmed by a timed
urinary collection (4 or 24 h). Microalbu-
minuria was deﬁned as ACR 3.5 mg/
mmol for women and 2.5 mg/mmol for
men; macroalbuminuria was deﬁned as
ACR 25 mg/mmol. CKD was deﬁned as
estimated glomerular ﬁltration rate
(eGFR) 60 ml/min per 1.72 m
2 deter-
mined by the Chinese-modiﬁed Modiﬁ-
cation of Diet in Renal Disease equation:
186  (SCR  0.011)
1.154 
(age)
0.203  (0.742 if female)  1.233,
where SCR is serum creatinine expressed
Table 1—Baseline clinical and biochemical characteristics and drug usage in type 2 diabetic patients stratiﬁed by number of risk-conferring
genotypes of ALR2 including the z2 (CA)n and C-106T polymorphisms
Baseline parameters No risk genotypes 1 risk genotype 2 risk genotypes P value
n 399 532 143
Age (years) 60 (51–68) 61 (50–69) 61 (51–68) 0.954*
Sex (% male) 57.4 59.2 62.9 0.509†
Duration of diabetes (years) 7.5 (1.0–12.0) 8.0 (2.0–12.0) 7.0 (2.0–12.0) 0.819*
Smoking status 0.681†
Ex-smoker (%) 17.3 13.9 16.2
Current smoker (%) 12.6 13.2 14.1
BMI (kg/m
2) 24.2 (22.1–26.9) 24.5 (22.2–26.6) 21.4 (21.8–26.1) 0.515*
Waist circumference (cm)
Men 88.0 (82.0–94.0) 87.5 (81.0–93.0) 88.0 (82.6–92.0) 0.760*
Women 82.0 (76.0–88.0) 83.0 (77.0–89.0) 82.0 (75.5–88.0) 0.395*
Obesity (%)‡ 57.4 57.4 57.3 1.000†
Systolic blood pressure (mmHg) 135 (120–147) 132 (119–146) 133 (120–149) 0.511*
Diastolic blood pressure (mmHg) 79 (70–86) 79 (70–85) 79 (74–85) 0.350*
Hypertension (blood pressure 140/90 mmHg
or medication) 45.6 49.3 46.9 0.520†
Family history of premature CVD (%) 1.8 0.8 0.7 0.311†
Retinopathy (%) 20.6 25.0 29.4 0.076†
Sensory neuropathy (%) 19.3 23.3 23.1 0.315†
Peripheral arterial disease (%) 5.0 8.6 7.7 0.101†
History of stroke (%) 1.8 2.4 3.5 0.480†
A1C (%) 7.4 (6.6–8.6) 7.6 (6.7–8.9) 7.5 (6.6–8.4) 0.285
Triglyceride (mmol/l) 5.30 (4.60–6.10) 5.30 (4.70–6.10) 5.40 (4.50–6.10) 0.962*
LDL cholesterol (mmol/l) 3.30 (2.70–4.00) 3.40 (2.80–4.00) 3.30 (2.70–3.95) 0.765*
HDL cholesterol (mmol/l) 1.24 (1.03–1.54) 1.24 (1.03–1.50) 1.31 (1.10–1.57) 0.110*
Spot urine ACR ratio (mg/mmol) 1.29 (0.59–5.53) 1.37 (0.64–8.79) 1.97 (0.69–24.7) 0.245*
Microalbuminuria (%) 17.2 21.0 19.7
0.150† Macroalbuminuria (%) 17.9 18.9 25.4
Serum creatinine (mol/l) 71.0 (58.0–85.0) 69.0 (59.0–84.0) 68.0 (62.0–85.5) 0.811*
Glomerular ﬁltration rate (ml/min per 1.73m
2) 113.5 (99.0–134.7) 115.7 (94.9–136.6) 115.3 (93.3–136.4) 0.918*
Use of medications at enrollment
Insulin (%) 12.3 15.2 19.6 0.096†
OAD (%) 50.6 50.0 52.4 0.873†
Insulin and OAD (%) 5.5 7.7 7.0 0.419†
Lipid-regulating drug (%) 3.8 4.1 4.9 0.840†
ACEI/ARB (%) 7.0 7.3 7.7 0.962†
Other antihypertensive drugs (%) 17.0 21.1 22.4 0.219†
Clinical end points after 8-year follow-up
CHD (%) 4.8 9.0 5.6 0.032†
Renal end point (%) 15.0 20.5 27.3 0.004†
Cardiorenal end point (%) 17.0 25.4 28.7 0.002†
All-cause death (%) 10.5 11.5 14.0 0.537†
Data are median (IQR) or %. *Derived from Kruskal-Wallis test. †Derived from 
2 test. ‡Obesity was deﬁned as BMI 25 kg/m
2 or waist 80 cm in women or 90
cm in men. ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; CVD, cardiovascular disease; OAD, oral antidiabetic drug.
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grams per deciliter converted to micro-
moles per liter) and 1.233 is the adjusting
coefﬁcient for Chinese (9).
The genetic assay and analysis, de-
scribed previously (5), were applied to
this expanded cohort, which contains
the reported case-control cohort of 213
patients.Thirteenallelesofthe5-(CA)n
microsatellite were identiﬁed including
z12, z10, z8, z6, z4, z2, z,
z2, z4, z6, z12, z14, and
z16,wherezcorrespondedto24(CA)
repeats. z2, z, and z2 accounted for
81.4% of total alleles. The genotypic
frequencies were in Hardy-Weinberg
equilibrium.
Clinical end points
In this cohort of 1,327 type 2 diabetic
patients enrolled consecutively between
1995 and 1998, 8 had type 1 diabetes,
206 had CKD, and 39 had CHD deﬁned
as a history of myocardial infarction, re-
vascularization, or typical chest pain with
apositivestresstestorabnormalcoronary
vasculature on imaging. These patients
were excluded and, thus, 1,074 patients
were included in the analysis.
The Hong Kong Hospital Authority is
the governing body of all 48 publicly
fundedhospitalsandclinics.Hospitaldis-
charge diagnoses, causes of death, and
laboratory results for determination of
eGFR were extracted from various Hong
Kong Hospital Authority databases up to
30 July 2005. All discharge diagnoses
were coded using the ICD-9. Causes of
death were validated by records in the
Hong Kong Death Registry.
The end point of CHD was deﬁned as
nonfatal myocardial infarction (code
410), ischemic heart disease (codes 411–
414), or death due to CHD (codes 410–
414). The renal end point was deﬁned as
1) fatal and nonfatal diabetes with renal
manifestations (code 250.4), CKD (code
585), or unspeciﬁed renal failure (code
586) (diagnosis 1–5); 2) dialysis (ICD-9
procedure code 39.95) or peritoneal dial-
ysis (ICD-9 procedure code 54.98); or 3)
ﬁrst event of eGFR 60 ml/min per 1.73
m
2 before the censor date. Follow-up
time was calculated from the enrollment
date to the date of the ﬁrst cardiorenal
eventordeathor30July2005,whichever
came ﬁrst.
Statistical analysis
All data are expressed as median (inter-
quartile range [IQR]) or as a percentage.
Kruskal-Wallis and 
2 tests were used to
compare continuous and categorical vari-
ables, including genotype and allele fre-
quency as appropriate. Multivariable Cox
proportional hazards regression was used
to obtain the hazard ratio (HR) (95% CI)
of baseline variables for prediction of
CHD, renal, and composite cardiorenal
end points. A proportional hazards as-
sumption was checked using the
Supremum test, which was imple-
mented using the ASSESS statement in
the SAS procedure PROC PHREG (Sta-
tistical Analysis System release 9.10;
SAS Institute, Cary, NC). P  0.05 was
considered to violate the assumption. If
indicated, stratiﬁed Cox regression was
used to adjust for the violation of pro-
portionality. The Kaplan-Meier estima-
tor with a log-rank test for linear trend
was used to examine the overall differ-
ence of survival functions stratiﬁed by the
number of genotypes of interest. All analy-
ses unless speciﬁed were performed using
SPSSforWindows(release13.0;SPSS,Chi-
cago,IL).P0.05(two-tailed)wasconsid-
ered to be signiﬁcant.
Sample size estimation
To obtain a stable Cox regression model,
10 events per predictor are generally rec-
ommended. Based on our previous anal-
ysis, the incidence of CHD in Chinese
type 2 diabetic patients was 9.28 (95% CI
8.31–10.24) per 1,000 person-years with
seven predictors (age, male sex, disease
duration, albuminuria, eGFR, smoking,
and non-HDL cholesterol) (7). Using the
lower limit of the CIs for estimation, a
prospective cohort of 8,424 person-years
[(70 	 8.31)  1,000] is required to de-
velop a stable model to predict CHD. For
ESRD, the event rate was 8.7 (7.8–9.6)
per 1,000 person-years with hematocrit
and ACR as predictors (8). A prospective
cohort of 2,571 person-years is required
to develop a stable model to predict
ESRD.Thetotalobservationperiodofthis
cohort was 8,592 person-years, which
givessufﬁcientpowertocomputeamodel
using cardiorenal end points.
RESULTS— Inthisprospectivecohort
(n  1,074, 59% men), the median (IQR)
age was 61 (50–69) years with a disease
duration of 7 (2–12) years. The total
observational period was 8.4 (5.6–9.3)
years with follow-up duration of 8,592
person-years. The annualized event
Table 2—Genotype and allele frequencies of the z2 allele of the 5 - (CA)n microsatellite and C-106T promoter polymorphisms in patients
stratiﬁed by the development of cardiorenal end points in type 2 diabetes
ALR2 (CA)n polymorphism ALR2 C-107T polymorphism
x/xx /z2z 2/z2 x z2C C C TT T C T
Cardiac end point
No 0.61 (611) 0.33 (324) 0.06 (64) 0.77 (1,546) 0.79 (118) 0.64 (633) 0.31 (312) 0.05 (54) 0.79 (1,578) 0.74 (111)
Yes 0.63 (47) 0.32 (24) 0.05 (4) 0.23 (452) 0.21 (32) 0.52 (39) 0.44 (33) 0.04 (3) 0.21 (420) 0.26 (39)
P 0.925 0.796* 0.715 0.073 0.050† 0.151
Renal end point
No 0.63 (548) 0.31 (266) 0.06 (52) 0.82 (1,362) 0.18 (302) 0.64 (553) 0.31 (269) 0.05 (44) 0.81 (1,375) 0.19 (314)
Yes 0.53 (110) 0.39 (82) 0.08 (16) 0.76 (370) 0.24 (114) 0.57 (119) 0.37 (76) 0.06 (13) 0.78 (357) 0.22 (102)
P 0.022 0.006* 0.008 0.204 0.075† 0.081
Cardiorenal end point
No 0.63 (522) 0.31 (257) 0.06 (51) 0.78 (1,301) 0.22 (363) 0.65 (537) 0.30 (249) 0.05 (44) 0.78 (1,323) 0.22 (366)
Yes 0.56 (136) 0.37 (91) 0.07 (17) 0.74 (359) 0.26 (125) 0.55 (135) 0.39 (96) 0.05 (13) 0.73 (337) 0.27 (122)
P 0.128 0.044* 0.064 0.021 0.008† 0.026
Study population 0.61 (658) 0.33 (348) 0.06 (68) 0.77 (1,664) 0.23 (484) 0.63 (672) 0.32 (345) 0.05 (57) 0.79 (1,689) 0.21 (459)
Data are frequency (n). *P value refers to risk association based on the combined genotype frequency of x/z2 and z2/z2 versus x/x genotype. †P value refers
to risk association based on the combined genotype frequency of CT and TT versus CC genotype.
ALR2 genotypes and cardiorenal complications
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end points were 8.92 (95% CI 6.91–
10.93), 25.98 (22.49–29.46), and
31.15(27.30–35.00)per1,000person-
years, respectively.
The clinical proﬁle including use of
medications among patients with 0, 1, 2,
or 3 risk-conferring genotypes were
similar at baseline. Compared with pa-
tients without the z2 and T allele, those
with either one or both of the risk-
conferring alleles had a higher incidence
ofCHD,renal,andcardiorenalendpoints
but similar death rates (Table 1). Patients
who developed a renal end point had a
higher frequency of z2/x or z2/z2
genotype (47 vs. 37%, P  0.006) and
z2 allele (24 vs. 18%, P  0.008) than
those without a renal end point. Patients
who developed cardiorenal end points
also had a higher frequency of the CT/TT
genotype (44 vs. 35%, P  0.008) and T
allele (27 vs. 22%, P  0.026) than those
who did not (Table 2).
Onmultivariableanalysis,thez2al-
lele of (CA)n and C-106T polymor-
phisms of ALR2 were selected as
independent predictors for renal or car-
diorenal end points along with age, male
sex, and smoking status. The presence of
tworisk-conferringgenotypesconferreda
twofold increased risk of renal or cardio-
renal end points (Table 3). Figures 1 and
2showthecumulativeeffectsofanumber
of risk-conferring genotypes on renal and
cardiorenal end points.
CONCLUSIONS— In this 8-year
prospective analysis of 1,074 type 2 dia-
betic patients with a low prevalence of
riskfactorsandcomplicationsandamean
A1Cof7.4%atenrollment,weconﬁrmed
our previous ﬁndings (5) regarding the
independent and additive effects of the
two genetic polymorphisms on the pro-
moterregionofALR2onrenalandcardio-
renalendpoints.Thesetwofoldincreased
risks were independent of other risk fac-
tors,notablyA1C,triglycerides,albumin-
uria, renal function, smoking status, and
treatments. Our results also lend support
to ALR2 as a candidate gene located in
chromosome 7, one of the most repro-
duciblechromosomalregionsfordiabetic
nephropathy (10). Conﬂicting results on
previous risk association studies of ALR2
are probably due to differences in study
design, patient selection, outcome mea-
surements, and sample size. The long
observation period and detailed docu-
mentation of clinical end points and con-
founders may contribute to our positive
ﬁndings, which are supported by experi-
mental studies regarding the adverse ef-
fects of glucotoxicity mediated through
oxidative stress, glycation end products,
cytokines, polyol, and growth factors (4).
In this respect, activation of protein ki-
nase C-
 and -ε in renal mesangial cells is
dependent on activation of the polyol
pathways in diabetic nephropathy (11).
The onset of CKD is associated with
anemia, vascular dysfunction and calciﬁ-
cation,metabolicacidosis,andinﬂamma-
tion, all of which are multipliers of CHD
risk (1). Asian patients have a lower risk
for CHD but a higher risk for stroke and
ESRD than their Caucasian counterparts
Table 3—HRs of predictors for cardiorenal end points in type 2 diabetes
Predictors
CHD Renal end point* Cardiorenal end point
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Basic models†
Age (years) 1.04 (1.02–1.06) 0.001 1.03 (0.99–1.06) 0.197 1.05 (1.04–1.07) 0.001
Sex (male) 0.81 (0.44–1.49) 0.498 0.91 (0.64–1.30) 0.609 0.81 (0.58–1.13) 0.208
Smoking status
Ex-smoker 1.72 (0.87–3.39) 0.120 1.25 (0.82–1.90) 0.293 1.22 (0.83–1.80) 0.317
Current smoker 1.81 (0.88–3.72) 0.108 1.46 (0.93–2.29) 0.099 1.50 (1.00–2.25) 0.053
ALR2 z2
/or z2
/ 0.99 (0.62–1.59) 0.972 1.52 (1.15–2.00) 0.003 1.35 (1.05–1.75) 0.020
ALR2 CT/TT 1.54 (0.98–2.42) 0.064 1.36 (1.03–1.79) 0.030 1.45 (1.12–1.87) 0.004
Risk associations with number of
risk genotypes
0 Reference Reference Reference
1 1.94 (1.14–3.30) 0.015 1.36 (0.99–1.87) 0.056 1.53 (1.14–2.05) 0.004
2 1.20 (0.52–2.75) 0.665 2.07 (1.38–3.11) 0.001 1.91 (1.29–2.82) 0.001
Adjusted models‡
Age (years) 1.02 (1.00–1.05) 0.103 1.04 (1.00–1.09) 0.064 1.03 (1.01–1.04) 0.002
Sex (male) 0.79 (0.41–1.51) 0.468 1.31 (0.88–1.86) 0.180 1.08 (0.75–1.55) 0.679
Smoking status
Ex-smoker 1.60 (0.79–3.23) 0.191 1.14 (0.73–1.76) 0.562 1.24 (0.83–1.87) 0.297
Current smoker 1.55 (0.74–3.24) 0.249 1.93 (1.20–3.11) 0.007 1.83 (1.19–2.81) 0.006
ALR2 z2
/or z2
/ 1.06 (0.65–1.72) 0.824 1.55 (1.15–2.08) 0.004 1.31 (1.01–1.72) 0.047
ALR2 CT/TT 1.44 (0.89–2.34) 0.137 1.53 (1.13–2.06) 0.005 1.49 (1.14–1.95) 0.004
Risk associations with number of
risk genotypes
0 Reference Reference Reference
1 2.05 (1.15–3.63) 0.014 1.37 (0.97–1.93) 0.073 1.44 (1.05–1.97) 0.023
2 1.18 (0.49–2.84) 0.706 2.41 (1.57–3.70) 0.001 1.94 (1.29–2.91) 0.002
*StratiﬁedCoxregressionmodelwasused(stratiﬁedonquartilesofage).†Basicmodelsareadjustedforage,sex,andsmokingstatus.‡Adjustedmodelsareadjusted
for age, sex, smoking status, duration of diabetes, BMI, systolic blood pressure, A1C, lipids (LDL cholesterol, HDL cholesterol, and triglycerides), log10(1  ACR),
and log10(eGFR). Use of log10(1  ACR) other than log10(ACR) was to avoid calculation of log10(0).
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anemia (13) and eGFR (14) are indepen-
dent risk factors for CHD, suggesting that
in populations in whom obesity and hy-
percholesterolemia are less prevalent
(15), CKD may take on a more important
role in determining CHD risk. Thus,
given the intimate relationship between
hyperglycemia and renal dysfunction and
the fact that ALR2 can interact with other
factors to promote atherosclerosis (16),
the risk conferred by the ALR2 genotype
on the cardiorenal end point, which was
morepowerfulthanthatofageandsmok-
ing, was noteworthy, at least in Chinese
populations. Our results remain robust
after excluding the small number of pa-
tients in our previous case-control cohort
(5) and adjustment for other confound-
ers.Apartfromthesetwogeneticvariants,
whichwerenotinlinkagedisequilibrium,
we did not detect risk association with
other microsatellite markers.
Optimal risk factor control reduces
complicationratesintype1(17)andtype
2 (18) diabetes. Type 1 diabetic patients
with one copy or more of the z2 allele
had a sevenfold increased risk of ne-
phropathy than those without, with z2
carriers having higher mRNA expression.
Asimilarrelationshipwasnotobservedin
nondiabetic subjects, suggesting that hy-
perglycemia might modulate the risk for
diabetic nephropathy through gene-
environment interactions (19). Because
multiple risk factors may inﬂuence pro-
gression of diabetic nephropathy, aggres-
sive control of modiﬁable risk factors
such as blood pressure, lipids, and glu-
cose in patients carrying a risk-conferring
genotype may be warranted although a
randomized study or decision analysis is
needed to test this hypothesis.
Several ALR2 inhibitors have been
used with limited success in patients with
diabetic nephropathy (20). In this light,
despite optimization of therapies, type 2
diabetic patients with nephropathy have
substantial residual risk of ESRD. In the
Asian subgroup analysis of the Reduction
of Endpoints in NIDDM with the Angio-
tensin II Antagonist Losartan (RENAAL)
Study, 10% of type 2 diabetic patients
with nephropathy continued to develop
ESRD on a yearly basis despite optimal
risk factor control and inhibition of the
renin-angiotensin system (21). Given the
antiproteinuric effects of ALR2 inhibitors
(20) and the fact that reduction in protein-
uria predicts future risk of cardiorenal end
points (21), our ﬁndings raise the possibil-
ity of using pathway-speciﬁc treatment to
further reduce risk of complications.
Study limitations
Although ideally these results should be
replicated in an independent cohort, we
do not know of any similar prospective
Asian cohorts to control for the con-
founder of ethnicity. There are inherent
measurement errors of albuminuria and
eGFR and with increasing use of medica-
tions to control risk factors, we have used
death and hospitalizations as outcome
measures. Although there are limita-
tions with the use of ICD-9 codes and
potential errors due to loss of patients
who have emigrated, these numbers are
expected to be small because of the
heavily subsidized health care system in
Hong Kong. Finally, the large body of
experimental evidence and consistency
of results in both case-control and pro-
Figure 1—Cumulative incidence of renal end point stratiﬁed by the number of risk alleles of the
z2 allele of the 5-(CA)n microsatellite and C-106T promoter polymorphisms of the ALR2 gene
(Ptrend  0.003, log-rank test) in type 2 diabetes. ve, positive; -ve, negative.
Figure 2—Cumulative incidence of cardiorenal end point stratiﬁed by the number of risk alleles
ofthez2alleleofthe5-(CA)nmicrosatelliteandC-106TpromoterpolymorphismsoftheALR2
gene (Ptrend 0.002, log-rank test) in type 2 diabetes. ve, positive; -ve, negative.
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ity of our results.
In summary, our prospective data
support the pivotal importance of the
ALR2 pathway on renal complications
that further accentuates CHD risk. Given
the high rates of diabetes and nephropa-
thy, especially in Asian populations, the
use of biomarkers such as variants of
the ALR2 genotypes, which affect 30% of
the population, may identify high-risk
subjects for intensive and targeted pre-
ventive therapy.
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